These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15520063)

  • 1. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.
    Schneeweiss A; Diel I; Hensel M; Kaul S; Sinn HP; Unnebrink K; Rudlowski C; Lauschner I; Schuetz F; Egerer G; Haas R; Ho AD; Bastert G
    Ann Oncol; 2004 Nov; 15(11):1627-32. PubMed ID: 15520063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.
    Schneeweiss A; Goerner R; Hensel MA; Lauschner I; Sinn P; Kaul S; Egerer G; Beldermann F; Geberth M; Solomayer E; Grischke EM; Haas R; Ho AD; Bastert G
    Biol Blood Marrow Transplant; 2001; 7(6):332-42. PubMed ID: 11464976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.
    Hensel M; Schneeweiss A; Sinn HP; Egerer G; Solomayer E; Haas R; Bastert G; Ho AD
    Int J Cancer; 2002 Jul; 100(3):290-6. PubMed ID: 12115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
    Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
    J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.
    Nieto Y; Cagnoni PJ; Nawaz S; Shpall EJ; Yerushalmi R; Cook B; Russell P; McDermit J; Murphy J; Bearman SI; Jones RB
    J Clin Oncol; 2000 May; 18(10):2070-80. PubMed ID: 10811672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
    Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB
    Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.
    Schrama JG; Faneyte IF; Schornagel JH; Baars JW; Peterse JL; van de Vijver MJ; Dalesio O; van Tinteren H; Rutgers EJ; Richelt DJ; Rodenhuis S
    Ann Oncol; 2002 May; 13(5):689-98. PubMed ID: 12075736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.
    García-Carbonero R; Hidalgo M; Paz-Ares L; Calzas J; Gómez H; Guerra JA; Hitt R; Hornedo J; Colomer R; Cortés-Funes H
    J Clin Oncol; 1997 Oct; 15(10):3178-84. PubMed ID: 9336353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
    Jabro G; Wazer DE; Ruthazer R; Lum R; Sklar N; Goldman D; Enegess D; Erban J
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):273-80. PubMed ID: 10760419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
    Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
    Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support.
    Nieto Y; Franklin WA; Jones RB; Berman SI; Pellom J; Barón AE; Shpall EJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):415-25. PubMed ID: 15148495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer.
    Adkins D; Brown R; Trinkaus K; Maziarz R; Luedke S; Freytes C; Needles B; Wienski D; Fracasso P; Pluard T; Moriconi W; Ryan T; Hoelzer K; Safdar S; Rearden T; Rodriguez G; Khoury H; Vij R; DiPersio J
    J Clin Oncol; 1999 Jul; 17(7):2006-14. PubMed ID: 10561251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy.
    Braun S; Cevatli BS; Assemi C; Janni W; Kentenich CR; Schindlbeck C; Rjosk D; Hepp F
    J Clin Oncol; 2001 Mar; 19(5):1468-75. PubMed ID: 11230493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
    Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
    Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial.
    Coombes RC; Howell A; Emson M; Peckitt C; Gallagher C; Bengala C; Tres A; Welch R; Lawton P; Rubens R; Woods E; Haviland J; Vigushin D; Kanfer E; Bliss JM
    Ann Oncol; 2005 May; 16(5):726-34. PubMed ID: 15817602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years.
    Gebauer G; Fehm T; Merkle E; Jaeger W; Mitze M
    Anticancer Res; 2003; 23(5b):4319-24. PubMed ID: 14666645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.
    Damon LE; Hu WW; Stockerl-Goldstein KE; Blume KG; Wolf JL; Gold E; Cecchi GR; Irwin D; Glaspy J; Territo I; Miller W; Mason JR; Linker CA
    Biol Blood Marrow Transplant; 2000; 6(5):496-505. PubMed ID: 11063378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.